Hepatitis C virus (HCV) infection is a worldwide health problem, whose management has been revolutionized after the availability of sofosbuvir, a direct-acting antiviral (DAAs). Sofosbuvir is a HCV NS5B polymerase inhibitor. Antiviral regimens including sofosbuvir are associated with success rates >90%, even in the case of "difficult-to-treat" patients such as subjects with liver cirrhosis as well as prior null response to IFN and ribavirin.
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C / Gentile, Ivan; Maraolo, ALBERTO ENRICO; Buonomo, ANTONIO RICCARDO; Zappulo, Emanuela; Borgia, Guglielmo. - In: EXPERT OPINION ON DRUG DISCOVERY. - ISSN 1746-0441. - 10:12(2015), pp. 1363-1377. [10.1517/17460441.2015.1094051]
The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C
GENTILE, Ivan;MARAOLO, ALBERTO ENRICO;BUONOMO, ANTONIO RICCARDO;ZAPPULO, EMANUELA;BORGIA, GUGLIELMO
2015
Abstract
Hepatitis C virus (HCV) infection is a worldwide health problem, whose management has been revolutionized after the availability of sofosbuvir, a direct-acting antiviral (DAAs). Sofosbuvir is a HCV NS5B polymerase inhibitor. Antiviral regimens including sofosbuvir are associated with success rates >90%, even in the case of "difficult-to-treat" patients such as subjects with liver cirrhosis as well as prior null response to IFN and ribavirin.| File | Dimensione | Formato | |
|---|---|---|---|
|
Discovery of sofosbuvir.pdf
non disponibili
Descrizione: Articolo principale
Tipologia:
Versione Editoriale (PDF)
Licenza:
Accesso privato/ristretto
Dimensione
6.15 MB
Formato
Adobe PDF
|
6.15 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
